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Introduction

Lung Microbiome

Patients with chronic obstructive pulmonary disease (COPD)
are at high risk of developing community-acquired pneumonia
(CAP). We recently completed a secondary analysis of the
University of Louisville Pneumonia Study [1] and documented
an annual incidence of 9,369 patients with CAP per 100,000
COPD population [2]. We estimated that 506,953 adults with
COPD are hospitalized due to CAP in the United States every
year [2]. This incidence rate is almost 18-fold greater that the
incidence rate of CAP patients without COPD [2].

The differences in the lung microbiome from a normal lung to
a lung of a patient with COPD are depicted in Figure 2. In the
normal lung, the alveolar microbiome contains a low number
of organisms with a high diversity of bacterial communities
(Figure 2A). The microbiome in the normal lung is constituted
primarily of anaerobic organisms, with predominance of the
phylum Bacteroidetes [3]. Some microorganisms are living
freely in the alveolar space, in a planktonic form, but half
of the bacterial communities are attached to alveolar cells
[4]. The alveolar flora may impede the multiplication of new
arriving pathogenic bacteria by several mechanisms. A normal
microbiome may compete for attachment sites on alveolar cells,
may compete for essential bacterial nutrients, or may produce
antibacterial substances to inhibit the growth of pathogenic
bacteria.

Three interrelated factors play a role in the pathogenesis of CAP
in COPD patients: 1) abnormalities in the lung microbiome,
2) abnormalities in the lung immunity, and 3) the virulence of
the pathogen causing CAP (Figure 1). In this opinion piece we
would like to speculate that alterations of the lung microbiome
may be a critical factor in the increased susceptibility of CAP in
COPD patients.
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In the COPD patient there are alterations in the number
and types of organisms present in the lung microbiome, a
phenomenon known as dysbiosis [5]. In the COPD lung the
microbiome contains high number of microorganisms, with
a low diversity of bacterial communities. It is likely that
several of these organisms are living in cell-associated biofilm
communities (Figure 2B). The abnormal alveolar microbiome
of COPD patients may be unable to impede the multiplication
of invading pathogens, enhancing susceptibility to pneumonia.
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Figure 1 Interplay of lung microbiome, lung immunity and pneumonia
pathogen in the pathogenesis of CAP in COPD.
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Macrophages, surfactant, and oxygen levels play a role in
alveolar immunity. Alveolar macrophage phagocytosis of
new organisms arriving to the alveoli is a primary step in the
prevention of pneumonia [6]. Surfactant acts as a component of
the alveolar host defenses by binding to the surface of pathogens
arriving to the alveoli [7]. Opsonization of bacteria by surfactant
facilitates phagocytosis by alveolar macrophages. Normal
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Figure 2 Characteristics of lung microbiome in a normal lung (A) and a COPD lung (B).

oxygen level is important in alveolar immunity since hypoxemia
is associated to local inflammation and immune dysfunction [8].
Alveolar dysbiosis in COPD patients may enhance susceptibility
to pneumonia by producing abnormal macrophage function,
surfactant degradation and low oxygen levels.

such as Klebsiella pneumoniae or Escherichia coli as well as
Gram-negative non-fermenting bacilli such as Pseudomonas
aeruginosa [2,9]. According to the local epidemiology,
methicillin-resistant Staphylococcus aureus (MRSA) may also
cause CAP in patients with severe COPD.

Pneumonia Pathogen
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As the severity of COPD progresses over time, the risk for the
patient to develop CAP increases, and the number of pathogens
able to cause CAP expand (Figure 3). The patient with mild to
moderate COPD will be at risk of infection with the pathogens
causing CAP in non-COPD patients with the addition of betalactamase producing bacteria such as Haemophilus influenzae,
Moraxella catarrhalis, and Staphylococcus aureus. In
patients with severe COPD the list of likely organisms able to
cause CAP will extend to Gram-negative Enterobacteriaceae

The primary model of pneumonia pathogenesis in COPD
patients will start with the pneumonia pathogens arriving to
the alveoli in greater number due to more frequent episodes of
microaspiration. Once in the alveoli the pneumonia pathogens
will overcome the abnormal alveolar microbiota as well as the
abnormal alveolar immunity. The uncontrolled multiplication
of the pathogen will cause the development of pneumonia.
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Another possible model of pathogenesis of CAP in COPD
patients may include a combination of alveolar multiplication
of new pathogenic bacteria arriving to the alveoli associated to
uncontrolled multiplication of some of the species present in the
alveolar microbiota. In this type of pathogenesis, the etiology
of pneumonia will be polymicrobial, with a combination of
invading pathogenic bacteria plus bacteria normally present in
the alveoli.
A final model of pathogenesis may involve the uncontrolled
multiplication of some of the bacteria already present in
the alveolar microbiota. In this case, the etiologic agent of
pneumonia will be bacteria that typically constitute the alveoli
normal flora. This scenario may explain why in several COPD
patients with CAP an etiologic agent is not identified, since
alveolar microbiome bacteria cannot be isolated using regular
culture techniques.

Figure 3 Likely pathogens causing CAP in COPD patients according to
severity of COPD.
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Conclusion
The alveolar microbiome plays an important role in maintaining
a normal alveolar immunity. In patients with COPD, the
dysbiosis of alveolar microbiota may alter several elements
of alveolar immunity. In this opinion piece we speculate that
alveolar dysbiosis may be a primary reason for the increased
susceptibility to CAP in COPD patients.
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